IGF-1 LR3 1mg is a research-grade form of Long R3 Insulin-Like Growth Factor-1, an engineered peptide investigated for its interactions with insulin-like growth factor receptors and IGF-binding proteins (IGFBPs).
Researchers use IGF-1 LR3 to explore how structural modifications influence growth-factor signaling, cellular responses, and biological activity in controlled laboratory systems.
Because peptide identity and purity can influence experimental reproducibility, analytical documentation is particularly important when evaluating IGF-1 LR3 research materials.
A Certificate of Analysis (COA) helps researchers examine whether a tested batch meets defined analytical specifications.
This guide explains the molecular properties of IGF-1 LR3, its laboratory applications, the role of HPLC and mass spectrometry, and how researchers can interpret available purity documentation.
For material-specific information, see the IGF-1 LR3 1mg compound page at Orion Peptides.
What Is IGF-1 LR3?
IGF-1 LR3, also called Long R3 IGF-1, is an engineered analogue of insulin-like growth factor-1.
Naturally occurring human IGF-1 consists of 70 amino acids and plays an important role in cellular signaling associated with growth, development, and metabolism.
IGF-1 LR3 contains 83 amino acids and incorporates two structural modifications:
- An arginine substitution at amino acid position three.
- An additional 13 amino acids at the N-terminus.
These changes reduce the analogue’s binding affinity for several IGF-binding proteins.
This property makes IGF-1 LR3 useful for experiments examining the relationship between growth-factor availability, binding proteins, and receptor-mediated activity.
Unlike native IGF-1, which normally circulates in association with binding proteins, IGF-1 LR3 demonstrates altered protein-binding behavior.
However, reduced binding affinity does not automatically establish a longer plasma half-life or superior clinical effectiveness.
IGF-1 LR3 1mg: Molecular and Research Properties
Understanding the fundamental characteristics of IGF-1 LR3 is important when comparing research materials and interpreting published experiments.
| Property | IGF-1 LR3 |
|---|---|
| Full name | Long R3 Insulin-Like Growth Factor-1 |
| Alternative name | Long-[Arg3]-IGF-I |
| Peptide length | 83 amino acids |
| Parent molecule | Human IGF-1 |
| Structural modifications | Arg3 substitution and N-terminal extension |
| Primary signaling target | IGF-1 receptor |
| Binding-protein affinity | Reduced relative to native IGF-1 |
| Research applications | Cell signaling, IGFBP interactions, growth-factor biology |
| Orion compound quantity | 1 mg |
| Regulatory classification | Investigational research compound |
The molecular modifications distinguish IGF-1 LR3 from native IGF-1 and support its use in experimental systems.
How Does IGF-1 LR3 Work?
IGF-1 LR3 interacts with the insulin-like growth factor signaling system.
The IGF-1 receptor (IGF1R) is a receptor tyrosine kinase involved in regulating multiple cellular processes.
When activated, the receptor initiates intracellular signaling cascades associated with cellular growth, survival, and metabolism.
IGF-1 Receptor Activation
IGF1R activation is associated with signaling pathways including:
PI3K/Akt: Involved in cellular survival, metabolic signaling, and protein synthesis.
RAS/MAPK: Participates in cellular proliferation and differentiation.
These pathways are important in the broader IGF signaling network.
Experiments using IGF-1 LR3 can help researchers investigate the consequences of receptor activation under different laboratory conditions.
Reduced IGF-Binding Protein Affinity
One of the most distinctive characteristics of IGF-1 LR3 is its reduced interaction with IGFBPs.
These proteins regulate the distribution and biological availability of insulin-like growth factors.
The structural modifications in IGF-1 LR3 decrease its affinity for several IGFBPs, potentially increasing the fraction available to interact with receptors in certain experimental systems.
A study by Francis and colleagues investigated the biological activity of modified IGF-I analogues.
The researchers found that changes affecting binding-protein interactions could substantially alter biological potency in experimental assays.
Read Francis et al. (1992) on PubMed.
Why Is IGF-1 LR3 Purity Important?
Purity is an important analytical characteristic of a peptide research material.
During peptide synthesis, manufacturing and purification processes can produce or leave behind substances other than the intended compound.
These may include related peptide species, fragments, or other process-associated impurities.
In research applications, such substances can complicate the interpretation of experimental findings.
Purity and Experimental Reproducibility
Researchers need confidence that measured biological responses are associated with the intended experimental material.
Reliable purity assessment helps laboratories:
- Characterize the material being investigated.
- Identify certain impurities or related compounds.
- Compare analytical results across batches.
- Document experimental inputs.
- Assess consistency against defined specifications.
However, a high HPLC purity percentage does not establish that a compound is sterile, endotoxin-free, pharmaceutically suitable, or safe for human use.
These are separate analytical and regulatory considerations.
What Is a Certificate of Analysis (COA)?
A Certificate of Analysis is a document reporting analytical findings for a particular tested sample or batch.
For peptide materials, a COA may include information about identity, purity, quantity, and other quality characteristics.
The specific tests depend on the compound and the analytical program.
Information Commonly Included in a Peptide COA
| COA component | Purpose |
|---|---|
| Compound identity | Identifies the compound being tested |
| Batch number | Connects the report to the tested material |
| Analytical method | Describes the testing technique |
| Purity result | Reports measured purity under the specified method |
| Quantity or content | Evaluates the amount of material |
| Test date | Identifies when analysis was conducted |
| Acceptance criteria | States the applicable specifications |
| Result | Indicates the analytical finding |
An appropriate COA allows researchers to distinguish a general compound description from documented, batch-specific analytical results.
IGF-1 LR3 1mg COA: Orion Peptides Batch Documentation
Orion Peptides provides analytical documentation for its IGF-1 LR3 1mg research material.
The COA currently displayed on the compound page identifies batch 202602IGF1.
The published report lists the following results:
| Test | Reported result |
|---|---|
| Identity | IGF-1 LR3 — Pass |
| Purity | 99.12% by HPLC-DAD |
| Measured quantity | 1.11 mg |
| Endotoxin result | 0.402 EU/mL |
| Sterility test | No growth reported |
| Analysis date | February 28, 2026 |
| Report issue date | August 1, 2026 |
These figures are taken from the displayed analytical report for that batch.
They should not be interpreted as guarantees concerning future batches or as evidence of suitability for human administration.
Researchers should independently review the applicable report, laboratory details, sample identity, and analytical methodology.
The current documentation can be accessed through Orion Peptides’ COA Verification page.
HPLC Testing for IGF-1 LR3
High-performance liquid chromatography (HPLC) is widely used to evaluate peptide purity.
The method separates components of a sample according to their interactions with a chromatographic system.
A detector measures the resulting signals, which can be analyzed to estimate the relative contribution of different components.
What Does an HPLC Purity Result Mean?
An HPLC purity percentage generally describes the proportion of a measured chromatographic signal attributed to the target component under specified test conditions.
It does not necessarily represent the mass fraction of the target peptide in the entire vial.
For example, an HPLC purity result does not independently establish:
- Molecular identity.
- Absolute peptide content.
- Absence of all impurities.
- Sterility.
- Endotoxin status.
- Safety for clinical administration.
These characteristics require appropriate additional methods and validation.
Why Is the Test Method Important?
Different chromatographic conditions can produce different results.
Researchers should consider details such as the separation method, detector, integration procedure, and acceptance criteria.
Where relevant, orthogonal methods can provide additional information about the material.
Mass Spectrometry and Peptide Identity
Mass spectrometry (MS) is another analytical technique used to characterize peptide materials.
It measures mass-to-charge ratios of ions and can provide evidence supporting molecular identity.
For a modified peptide such as IGF-1 LR3, molecular identity is especially important because its sequence differs from native IGF-1.
Why Is Identity Testing Different From Purity Testing?
Purity testing examines the relative composition of an analyzed sample.
Identity testing helps establish whether the intended compound is present.
A chromatographically pure sample could still contain the wrong compound if molecular identity has not been independently established.
Therefore, purity and identity are complementary analytical characteristics rather than interchangeable claims.
Scientific Research on IGF-1 LR3
Several early studies investigated the distinctive biological properties of Long R3 IGF-I.
Francis et al. (1992): IGF Analogue Activity
Francis and colleagues investigated recombinant IGF-I analogues designed to alter interactions with IGF-binding proteins.
Their research helped demonstrate that modifying growth-factor binding characteristics could influence biological potency.
The study established an important foundation for understanding engineered IGF analogues.
Ballard et al. (1993): Binding Proteins and Plasma Clearance
Ballard and colleagues compared native IGF-I and LR3 IGF-I.
They reported markedly reduced IGFBP affinity for LR3 IGF-I and increased potency in certain cell-culture and animal experiments.
Importantly, the study also found that LR3 IGF-I was cleared from rat plasma more rapidly than native IGF-I.
This distinction demonstrates why reduced binding-protein affinity should not be equated automatically with longer circulation time.
What Do These Studies Establish?
The findings support IGF-1 LR3’s scientific relevance as an experimental analogue for investigating growth-factor signaling and binding-protein interactions.
However, they do not establish clinical safety, muscle-building effectiveness, or a therapeutic benefit in humans.
IGF-1 LR3 vs Native IGF-1: Research Differences
| Feature | Native IGF-1 | IGF-1 LR3 |
|---|---|---|
| Amino acids | 70 | 83 |
| Origin | Naturally occurring hormone | Engineered analogue |
| Position-three modification | None | Glu-to-Arg substitution |
| N-terminal extension | No | Yes |
| IGFBP binding | Greater affinity | Substantially reduced affinity |
| Research focus | Physiological IGF signaling | Modified IGF signaling and IGFBP interactions |
Although the molecules are closely related, their experimental behavior can differ.
These differences are particularly relevant when interpreting findings from cell cultures and animal models.
IGF-1 LR3 Safety and Research Limitations
IGF-1 LR3 has not been approved by the FDA for human therapeutic use.
Its available scientific literature is predominantly preclinical.
IGF-associated signaling pathways participate in glucose regulation, cellular proliferation, and other essential biological processes.
Uncontrolled exposure to growth-factor analogues may therefore raise important safety concerns.
For IGF-1 LR3 specifically, comprehensive human safety data are lacking.
Analytical purity, a Certificate of Analysis, or successful laboratory testing does not establish clinical safety.
Research findings should be interpreted within the experimental conditions under which they were obtained.
Frequently Asked Questions
What is IGF-1 LR3 1mg?
IGF-1 LR3 1mg is a laboratory research material containing Long R3 Insulin-Like Growth Factor-1, an engineered 83-amino-acid analogue of native IGF-1.
What does the LR3 modification mean?
The designation refers to a long analogue containing an arginine substitution at position three and an additional N-terminal sequence.
Why is IGF-1 LR3 used in research?
Researchers use it to investigate IGF receptor signaling, binding-protein interactions, and cellular responses to modified growth factors.
What does a COA verify?
A COA records analytical findings for a specific tested sample or batch. Depending on the methods used, it may report identity, purity, quantity, and additional quality characteristics.
Does 99% HPLC purity mean a peptide is safe?
No. HPLC purity is an analytical measurement and does not establish sterility, complete impurity characterization, pharmaceutical approval, or clinical safety.
Does Orion Peptides provide IGF-1 LR3 COA documentation?
Orion Peptides displays batch-specific COA information through its compound and verification pages. Researchers should confirm that the relevant documentation corresponds to the specific batch under examination.
Is IGF-1 LR3 FDA approved?
No. IGF-1 LR3 is not FDA approved for human therapeutic administration.
Conclusion
IGF-1 LR3 1mg is a modified insulin-like growth factor analogue used in experimental studies of receptor signaling and IGF-binding protein interactions.
Its molecular modifications alter its biological properties relative to native IGF-1, making it relevant to several areas of laboratory research.
For laboratories assessing research materials, purity testing and batch-specific Certificates of Analysis provide important analytical information.
However, these documents should not be confused with evidence of clinical safety or regulatory approval.
Researchers can examine the IGF-1 LR3 1mg material specifications and associated COA documentation through Orion Peptides.
Scientific References
- Francis GL et al. (1992). Novel Recombinant Fusion Protein Analogues of Insulin-Like Growth Factor (IGF)-I Indicate the Relative Importance of IGF-Binding Protein and Receptor Binding for Enhanced Biological Potency. PubMed.
- Ballard FJ et al. (1993). Effects of Interactions Between IGFBPs and IGFs on the Plasma Clearance and In Vivo Biological Activities of IGFs and IGF Analogs. PubMed.
- Ballard FJ et al. (1989). Effects of Insulin-Like Growth Factors on Protein Metabolism: Why Are Some Molecular Variants More Potent? PubMed.
- Orion Peptides. IGF-1 LR3 1mg — Compound Specifications and Batch COA. Compound documentation.
- Orion Peptides. Certificate of Analysis Verification. COA records.
Research disclaimer: This article is intended for scientific education and laboratory research information only. IGF-1 LR3 is not approved for human or veterinary administration. It is not intended for diagnostic, therapeutic, or dietary use.
